Humalog

PreclinicalSmall molecule

HHalozyme Therapeutics

Humalog is one of 43 small molecule programs targeting Insulin resistance. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Insulin ResistancePreclinical

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Insulin Resistance

#DrugCompanyPhaseTrials

Avandia

Jazz Pharmaceuticals

Approved

6 2

Glucophage

EMD Serono

Approved

17 3

Rozerem

Takeda

Approved

1 4

Crestor

AstraZeneca

Approved

1 5

Isordil

AstraZeneca

Approved

1 6

Victoza

Novo Nordisk

Approved

1 7

Calciferol

Jazz Pharmaceuticals

Approved

—8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 9

Tradjenta

Boehringer Ingelheim

Approved

1 10

Starlix

Novartis

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Infusion

NCT06532461

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus6 trials

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

Completed·HHalozyme Therapeutics·Phase 2·NCT00774800·22 enrolled

A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus

Completed·AAdocia·Phase 1·NCT03916640·24 enrolled

A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus

Completed·AAdocia·Phase 1·NCT03512236·24 enrolled

Show 3 more trials

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Completed· Sanofi logo

Sanofi·Phase 3·NCT02273180·507 enrolled

Environmental Effects Type 1 Diabetes Mellitus

Completed·UUniversity of Hull·N/A·NCT03102476·10 enrolled

To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus

Completed·AAdocia·Phase 1·NCT02528396·36 enrolled

Type 1 Diabetes4 trials

A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes

Completed·AAdocia·Phase 2·NCT02146651·38 enrolled

Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration

Completed·BBiodel·Phase 1·NCT01908894·12 enrolled

A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Completed·AAdocia·Phase 1/2·NCT02213146·38 enrolled

Show 1 more trial

A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Completed·AAdocia·Phase 1·NCT02029924·37 enrolled

Type 2 Diabetes Mellitus3 trials

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed·HHalozyme Therapeutics·Phase 2·NCT00916357·23 enrolled

A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus

Completed·AAdocia·Phase 1·NCT02562326·51 enrolled

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Completed· Sanofi logo

Sanofi·Phase 3·NCT02294474·505 enrolled

Type 2 Diabetes2 trials

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02514850·24 enrolled

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02915250·36 enrolled

Hyperglycemia2 trials

Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

Withdrawn·EEmory University·Phase 4·NCT01971047

Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia

Completed·UUniversity of Florida·N/A·NCT01621776·107 enrolled

9 more indications

Infusion2 trials

A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®

Completed·AAdocia·Phase 1·NCT02562313·80 enrolled

A Trial of Three- and Seven-days Insulin Infusions Set

Recruiting·SSteno Diabetes Center Copenhagen·N/A·NCT06532461·80 enrolled

MPA1 trial

Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal

Completed·AAdocia·Phase 1·NCT02344992·38 enrolled

Tics1 trial

A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro to Humalog® in Healthy Subjects

Completed·GGeropharm·N/A·NCT03604575·28 enrolled

GAN1 trial

Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro

Withdrawn·GGan and Lee Pharmaceuticals, USA·Phase 3·NCT04254380

Insulin resistance1 trial

Is Brain Insulin Resistance a Feature of the Biology of Depression in Adolescents

Active, not recruiting·CCentre for Addiction and Mental Health·N/A·NCT05571878·24 enrolled

Single Dose1 trial

An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects

Completed·AAdocia·Phase 1·NCT02660502·15 enrolled

Trial1 trial

A Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of THDB0206 Injection in Healthy Chinese Subjects

Completed·TTonghua Dongbao Pharmaceutical Co.,Ltd·Phase 1·NCT06153329·39 enrolled

TED1 trial

Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas

Terminated·MMassachusetts General Hospital·Phase 2/3·NCT03262116·20 enrolled

Unspecified1 trial

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

Completed·HHalozyme Therapeutics·Phase 1·NCT00705536·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Humalog. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Humalog compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Humalog. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Halozyme Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHalozyme Therapeutics

Humalog

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Type 1 Diabetes Mellitus6 trials

Type 1 Diabetes4 trials

Type 2 Diabetes Mellitus3 trials

Type 2 Diabetes2 trials

Hyperglycemia2 trials

Infusion2 trials

MPA1 trial

Tics1 trial

GAN1 trial

Insulin resistance1 trial

Single Dose1 trial

Trial1 trial

TED1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News